07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Basilea, Grupo Biotoscana deal

Basilea granted Grupo Biotoscana exclusive rights to commercialize Cresemba isavuconazole and Zevtera ceftobiprole in 19 Latin American countries, including Argentina, Brazil, Columbia and Mexico. Basilea will receive CHF11 million ($11.3 million) up front and is...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Grupo Farmaceutico Biotoscana S.A. deal

Toby Sykes, a principal at VC firm Essex Woodlands Health Ventures, said Essex and fellow VC firm Advent International acquired an undisclosed controlling stake in Biotoscana for an undisclosed sum at the end of 2011....
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

Biotoscana Farma International, Vanda deal

Vanda granted Biotoscana's Biotoscana Farma S.A. subsidiary exclusive commercialization rights to schizophrenia drug Fanapt iloperidone in Argentina. Biotoscana is responsible for regulatory approval of the serotonin (5-HT2) receptor and dopamine receptor antagonist. Vanda will supply...